TREATMENT OF ACTIVE SLE AND THE PREVENTION OF SUBSEQUENT LUPUS FLARES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是调查阿巴西普是否将具有更大的临床疗效相比，安慰剂在糖皮质激素的共同背景下，在治疗患有系统性红斑狼疮（SLE）的患者，谁表现出最近活跃（“进入耀斑”）表现的SLE。入组发作表现包括：符合不列颠群岛狼疮评估组（BILAG）“A”或“B”标准的关节炎、胸膜炎/心包炎和/或盘状皮肤病变。具体而言，该研究将检查阿巴西普是否会防止这些最近活跃的耀斑患者在逐渐减少用于达到初始控制入口耀斑的糖皮质激素时发生后续耀斑。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate whether abatacept will have a greater clinical efficacy compared to placebo on a common background of glucocorticosteroids in treating patients with systemic lupus erythematosus (SLE) who have exhibited recently active ("entry flare") manifestions of SLE. Entry flare manifestations include: arthritis, pleuritis/pericarditis, and or/discoid cutaneous lesions satisfying the British Isles Lupus Assessment Group (BILAG) "A" or "B" criteria. Specifically, the study will examine whether abatacept will prevent patients with these recently active flares from developing subsequent flares when tapering the glucocorticosteroids used to attain initial control of the entry flare.